Element Biosciences

Element Biosciences

Element Biosciences was incorporated in July 2017 and is headquartered in San Diego, California. The company was founded by a team of scientists and engineers from the genomics industry who identified an opportunity to challenge established sequencing incumbents with a more affordable, high-accuracy benchtop platform. The firm develops and markets DNA sequencing and multiomic analysis instruments. Its core product lines include the AVITI sequencing platform and the AVITI24 multiomic system, which enables spatial co-detection of RNA, protein, and cell morphology in 24 hours via ABC Sequencing. Asset classes span life sciences hardware, chemistry, and software. The company claims to hold nearly 30 unique patents and to have supported over 400 publications. Its customer base includes the Broad Institute and Google Health Genomics, and its systems are deployed across 40-plus countries. Element does not publicly disclose its financial backers or ownership structure; it is not listed on a public exchange. The firm raised an undisclosed amount from institutional investors during its formation and has not reported additional funding rounds. As of mid-2026, it employs several hundred people and maintains its single headquarters in San Diego. A structural differentiator is Element's dual-platform strategy: the AVITI24 system combines sequencing with spatial imaging on a single integrated platform, eliminating library prep and separate data workflows. That integrated approach contrasts with competitors that separate sequencing and spatial biology into distinct instrument lines, creating a technical moat for Element in the multiomic analysis market.